Compare EVGO & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | OABI |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | 376 | 89 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.7M | 294.3M |
| IPO Year | N/A | N/A |
| Metric | EVGO | OABI |
|---|---|---|
| Price | $1.59 | $3.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $5.23 | $4.50 |
| AVG Volume (30 Days) | ★ 3.6M | 458.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.45 | $52.42 |
| Revenue Next Year | $29.44 | $64.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $1.32 |
| 52 Week High | $5.18 | $3.12 |
| Indicator | EVGO | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 83.44 |
| Support Level | $1.41 | $1.84 |
| Resistance Level | $2.30 | N/A |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 48.61 | 95.70 |
EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.